Protara Therapeutics IncNASDAQ:TARA
- LAST PRICE3.0100
- TODAY'S CHANGE (%)-0.0300 (-0.9868%)
- Bid / Lots2.9500/ 100
- Ask / Lots3.0000/ 2
- Open / Previous Close3.0600 / 3.0400
- Day Range
- 52 Week Range
- Volume268,422
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TARA |
|---|---|---|
| 09:32 ET | 2697 | 3.11 |
| 09:33 ET | 2776 | 3.0301 |
| 09:35 ET | 6610 | 3.15 |
| 09:37 ET | 16635 | 3.2 |
| 09:39 ET | 8815 | 3.17 |
| 09:42 ET | 1253 | 3.15 |
| 09:44 ET | 1100 | 3.175 |
| 09:48 ET | 6613 | 3.13 |
| 09:50 ET | 12200 | 3.15 |
| 09:51 ET | 900 | 3.1 |
| 09:53 ET | 200 | 3.1 |
| 09:57 ET | 100 | 3.13 |
| 10:02 ET | 100 | 3.13 |
| 10:04 ET | 1000 | 3.13 |
| 10:06 ET | 500 | 3.114 |
| 10:09 ET | 300 | 3.1144 |
| 10:11 ET | 588 | 3.12 |
| 10:15 ET | 100 | 3.115 |
| 10:18 ET | 1300 | 3.14 |
| 10:20 ET | 200 | 3.12 |
| 10:22 ET | 1805 | 3.15 |
| 10:24 ET | 11007 | 3.16 |
| 10:26 ET | 2184 | 3.175 |
| 10:27 ET | 3193 | 3.13 |
| 10:29 ET | 469 | 3.12 |
| 10:31 ET | 595 | 3.18 |
| 10:33 ET | 100 | 3.18 |
| 10:38 ET | 851 | 3.19 |
| 10:44 ET | 200 | 3.175 |
| 10:47 ET | 100 | 3.175 |
| 10:49 ET | 100 | 3.175 |
| 10:51 ET | 700 | 3.19 |
| 10:54 ET | 827 | 3.2 |
| 10:56 ET | 5978 | 3.2 |
| 10:58 ET | 37522 | 3.16 |
| 11:00 ET | 648 | 3.16 |
| 11:02 ET | 20598 | 3.044 |
| 11:07 ET | 1728 | 3.06 |
| 11:14 ET | 1500 | 3.09 |
| 11:16 ET | 3200 | 3.1 |
| 11:20 ET | 5200 | 3.115 |
| 11:25 ET | 900 | 3.1 |
| 11:27 ET | 600 | 3.1 |
| 11:30 ET | 200 | 3.1 |
| 11:32 ET | 100 | 3.08 |
| 11:34 ET | 1600 | 3.07 |
| 11:36 ET | 14002 | 3.045 |
| 11:38 ET | 12490 | 3 |
| 11:39 ET | 1100 | 3 |
| 11:43 ET | 1315 | 3 |
| 11:45 ET | 6500 | 3 |
| 11:48 ET | 200 | 3 |
| 11:50 ET | 500 | 3 |
| 11:52 ET | 8978 | 3 |
| 11:54 ET | 803 | 2.93 |
| 11:56 ET | 1300 | 2.92 |
| 11:57 ET | 1700 | 2.96 |
| 11:59 ET | 487 | 2.96 |
| 12:01 ET | 7729 | 2.9523 |
| 12:03 ET | 600 | 2.93 |
| 12:06 ET | 2378 | 2.96 |
| 12:10 ET | 1750 | 2.98 |
| 12:19 ET | 700 | 3.01 |
| 12:21 ET | 200 | 2.96 |
| 12:24 ET | 200 | 2.98 |
| 12:26 ET | 2324 | 2.98 |
| 12:28 ET | 300 | 2.98 |
| 12:30 ET | 365 | 2.985 |
| 12:32 ET | 1765 | 2.99 |
| 12:37 ET | 500 | 2.98 |
| 12:39 ET | 300 | 2.988 |
| 12:46 ET | 3566 | 3 |
| 12:48 ET | 4989 | 2.99 |
| 12:50 ET | 300 | 2.995 |
| 12:55 ET | 500 | 2.98 |
| 12:57 ET | 1400 | 2.98 |
| 01:00 ET | 2382 | 3.01 |
Nov 15, 2024
Nov 14, 2024
DJ Protara Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co., from 7:05AM ET on Thursday Nov 14, 2024 by Dow Jones
7:05AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
*DJ Protara Therapeutics 3Q Loss/Shr 50c >TARA, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 12, 2024 by Dow JonesProtara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 6, 2024
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Protara Therapeutics Inc | 62.7M | -1.1x | --- |
Entera Bio Ltd | 62.6M | -6.3x | --- |
Allovir Inc | 62.5M | -0.6x | --- |
Boundless Bio Inc | 59.3M | -1.0x | --- |
Aileron Therapeutics Inc | 59.4M | -0.9x | --- |
Immuneering Corp | 66.1M | -1.1x | --- |
Company Information
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Contact Information
- Headquarters
- 345 Park Avenue South, 3Rd FloorNEW YORK, NY, United States 10010
- Phone
- 646-844-0337
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Luke Beshar
- President, Chief Executive Officer, Director
- Jesse Shefferman
- Chief Financial Officer
- Patrick Fabbio
- Chief Scientific Operations Officer
- Jacqueline Zummo
- Controller
- Hannah Fry
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $62.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.77 |
EPS | $-2.82 |
Book Value | $6.01 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
